CoronaVR
Predicted highly potential T-cell epitopes (CD4)
| No | Protein | Epitope sequence | Start | Stop | Length | Core sequence | Conservancy |
|---|---|---|---|---|---|---|---|
| 1 | ORF8 | MKFLVFLGIITTVAA | 1 | 15 | 15 | FLVFLGIIT | None |
| 2 | ORF8 | FLGIITTVAAFHQEC | 6 | 20 | 15 | ITTVAAFHQ | None |
| 3 | ORF3 | SDFVRATATIPIQAS | 26 | 40 | 15 | FVRATATIP | None |
| 4 | ORF8 | YIRVGARKSAPLIEL | 46 | 60 | 15 | YIRVGARKS | None |
| 5 | ORF3 | LYLYALVYFLQSINF | 106 | 120 | 15 | LVYFLQSIN | SARS-CoV(80%) |
| 6 | N | DAALALLLLDRLNQL | 216 | 230 | 15 | LALLLLDRL | SARS-CoV(80%) |
| 7 | S | IGINITRFQTLLALH | 231 | 245 | 15 | ITRFQTLLA | None |
| 8 | NSP2 | KEKVNINIVGDFKLN | 456 | 470 | 15 | INIVGDFKL | 80% (SARS-CoV) |
| 9 | NSP2 | INIVGDFKLNEEIAI | 461 | 475 | 15 | INIVGDFKL | 86.7% (SARS-CoV) |
| 10 | NSP3 | EILGTVSWNLREMLA | 1366 | 1380 | 15 | ILGTVSWNL | 100% (SARS-CoV) |
| 11 | NSP3 | TIQRKYKGIKIQEGV | 1401 | 1415 | 15 | QRKYKGIKI | 93.33% (SARS-CoV) |
| 12 | NSP3 | YPSLETIQITISSFK | 2301 | 2315 | 15 | IQITISSFK | 80% (SARS-CoV) |
| 13 | NSP3 | TIQITISSFKWDLTA | 2306 | 2320 | 15 | TIQITISSF | 73.33% (SARS-CoV) |
| 14 | NSP3 | ISSFKWDLTAFGLVA | 2311 | 2325 | 15 | FKWDLTAFG | 66.67% (SARS-CoV) |
| 15 | NSP4 | AVGNICYTPSKLIEY | 2891 | 2905 | 15 | GNICYTPSK | 100% (SARS-CoV) |
| 16 | NSP4 | LMSFTVLCLTPVYSF | 3086 | 3100 | 15 | LMSFTVLCL | 80% (SARS-CoV) |
| 17 | 3C-like ptoteinase (NSP5) | LIRKSNHNFLVQAGN | 3321 | 3335 | 15 | IRKSNHNFL | 93.33% (SARS-CoV) |
| 18 | NSP6 | FLPFAMGIIAMSAFA | 3611 | 3625 | 15 | MGIIAMSAF | 60% (SARS-CoV) |
| 19 | NSP6 | LCLFLLPSLATVAYF | 3636 | 3650 | 15 | FLLPSLATV | 100% (SARS-CoV) |
| 20 | NSP6 | ASAVVLLILMTARTV | 3686 | 3700 | 15 | LILMTARTV | 93.33% (SARS-CoV) |
| 21 | NSP6 | LFCLLNRYFRLTLGV | 3796 | 3810 | 15 | LNRYFRLTL | 100% (SARS-CoV) |
| 22 | NSP6 | NRYFRLTLGVYDYLV | 3801 | 3815 | 15 | FRLTLGVYD | 100% (SARS-CoV) |
| 23 | NSP6 | YDYLVSTQEFRYMNS | 3811 | 3825 | 15 | LVSTQEFRY | 100% (SARS-CoV) |
| 24 | NSP7 | KCTSVVLLSVLQQLR | 3866 | 3880 | 15 | TSVVLLSVL | 100% (SARS-CoV), 80% (MERS CoV) |
| 25 | NSP8 | SEFSSLPSYAAFATA | 3946 | 3960 | 15 | FSSLPSYAA | 93.33% (SARS-CoV) |
| 26 | NSP8 | IIPLTTAAKLMVVIP | 4061 | 4075 | 15 | IPLTTAAKL | 93.33% (SARS-CoV) |
| 27 | NSP9 | DNALAYYNTTKGGRF | 4166 | 4180 | 15 | YNTTKGGRF | 86.67% (SARS-CoV) |
| 28 | NSP9 | IKGLNNLNRGMVLGS | 4231 | 4245 | 15 | LNNLNRGMV | 100% (SARS-CoV) |
| 29 | NSP9/NSP10 | MVLGSLAATVRLQAG | 4241 | 4255 | 15 | MVLGSLAAT | 100% (SARS-CoV) , 80% (MERS CoV) |
| 30 | RDRP (NSP12) | VDSYYSLLMPILTLT | 4626 | 4640 | 15 | YYSLLMPIL | 100% (SARS-CoV) |
| 31 | RDRP (NSP12) | PFVVSTGYHFRELGV | 4731 | 4745 | 15 | FVVSTGYHF | 100% (SARS-CoV), 80% (HKU1-CoV) |
| 32 | RDRP (NSP12) | RELGVVHNQDVNLHS | 4741 | 4755 | 15 | GVVHNQDVN | 100% (SARS-CoV) |
| 33 | RDRP (NSP12) | QDALFAYTKRNVIPT | 4916 | 4930 | 15 | FAYTKRNVI | 100% (SARS-CoV), 80% (MERS CoV), 80% HNL63 |
| 34 | Helicase (NSP13) | GKSHFAIGLALYYPS | 5611 | 5625 | 15 | IGLALYYPS | 100% (SARS-CoV), 80% (MERS CoV) |
| 35 | Helicase (NSP13) | YDLSVVNARLRAKHY | 5706 | 5720 | 15 | YDLSVVNAR | 100% (SARS-CoV), 80% (0C43) |
| 36 | Helicase (NSP13) | RAKHYVYIGDPAQLP | 5716 | 5730 | 15 | HYVYIGDPA | 100% (SARS-CoV), 80% (MERS CoV), 80% (HKU1), 80% (0C43) |
| 37 | 3'-5' Exonuclease (NSP14) | FKHLIPLMYKGLPWN | 6071 | 6085 | 15 | IPLMYKGLP | 100% (SARS-CoV) |
| 38 | 3'-5' Exonuclease (NSP14) | PLMYKGLPWNVVRIK | 6076 | 6090 | 15 | MYKGLPWNV | 100% (SARS-CoV) |
| 39 | 3'-5' Exonuclease (NSP14) | IGFDYVYNPFMIDVQ | 6156 | 6170 | 15 | VYNPFMIDV | 93.33% (SARS-CoV) |
| 40 | 3'-5' Exonuclease (NSP14) | KVQHMVVKAALLADK | 6236 | 6250 | 15 | MVVKAALLA | 93.33% (SARS-CoV) |
| 41 | 3'-5' Exonuclease (NSP14) | FDKSAFVNLKQLPFF | 6356 | 6370 | 15 | FVNLKQLPF | 93.33% (SARS-CoV) |
| 42 | Endo-RNAase (NSP15) | QLGGLHLLIGLAKRF | 6696 | 6710 | 15 | HLLIGLAKR | 86.67% (SARS-CoV) |
| 43 | Endo-RNAase (NSP15) | ELEDFIPMDSTVKNY | 6716 | 6730 | 15 | IPMDSTVKN | 93.33% (SARS-CoV) |
| 44 | 2'-O-ribose methyltransferase (NSP16) | SKFPLKLRGTAVMSL | 7046 | 7060 | 15 | FPLKLRGTA | 100% (SARS-CoV) |